Get the Stockscreener App
1.89
94.44%
-32.08
After Hours:
1.90
0.01
+0.53%
Meridian Bioscience Inc. stock is traded at $1.89, with a volume of 521.95K.
It is down -94.44% in the last 24 hours and down -94.44% over the past month.
Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for various gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms and technologies, including isothermal DNA amplification under the Alethia brand; rapid immunoassays, a single-use immunoassays under the ImmunoCard and ImmunoCard STAT! brand names; enzyme-linked immunoassays under the PREMIER brand; and anodic stripping voltammetry, an electrical chemical sensor platform for quantitative determination under the LeadCare brand. This segment's products are primarily used in the detection of infectious diseases caused by various bacteria, viruses, parasites, and pathogens. Its products consists of gastrointestinal assays, including tests for C. difficile, Enterohemorrhagic E. coli, Campylobacter jejuni, H. pylori, Cryptosporidium, giardia lamblia, and calprotectin; respiratory illness assays, such as tests for Group A Streptococcus, Influenza, M. pneumoniae, Bordetella pertussis, and respiratory syncytial virus; blood chemistry assays; and tests for Group B Streptococcus, Chlamydia trachomatis, Neisseria gonorrhea, Herpes Simplex Virus Type 1 and Type 2, and Malaria. This segment sells its products through direct sales force and independent distributors to acute care hospitals, reference laboratories, outpatient clinics, and physician office laboratories. The Life Science segment offers bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, competent cells, and bioresearch reagents used by researchers, agri-bio companies, and other diagnostic manufacturing companies. Meridian Bioscience, Inc. was founded in 1976 and is headquartered in Cincinnati, Ohio.
See More
Previous Close:
$33.97
Open:
$1.86
24h Volume:
521.95K
Relative Volume:
66.00
Market Cap:
$1.49B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
1.9286
EPS:
0.98
Net Cash Flow:
-
1W Performance:
-94.44%
1M Performance:
-94.44%
6M Performance:
-94.44%
1Y Performance:
-94.44%
1-Day Range:
$1.69
$1.9452
1-Week Range:
$1.69
$1.9452
52-Week Range:
$1.69
$1.9452
Meridian Bioscience Inc. Stock (VIVO) Company Profile
Name
Meridian Bioscience Inc.
Sector
Industry
Phone
513-271-3700
Address
3471 River Hills Drive, Cincinnati, OH
Compare VIVO vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VIVO
Meridian Bioscience Inc.
|
1.89 | 1.49B | 0 | 0 | 0 | 0.00 |
|
TMO
Thermo Fisher Scientific Inc
|
470.00 | 172.51B | 44.56B | 6.72B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
191.39 | 132.46B | 24.57B | 3.60B | 5.26B | 5.051 |
|
IDXX
Idexx Laboratories Inc
|
586.37 | 45.69B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
111.83 | 31.51B | 7.07B | 1.29B | 993.00M | 4.5355 |
|
WAT
Waters Corp
|
290.02 | 28.11B | 3.17B | 642.63M | 516.49M | 10.77 |
Meridian Bioscience Inc. Stock (VIVO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-11-20 | Resumed | Piper Sandler | Overweight |
| Jul-27-20 | Initiated | H.C. Wainwright | Buy |
| May-11-20 | Upgrade | William Blair | Mkt Perform → Outperform |
| May-01-19 | Upgrade | Piper Jaffray | Underweight → Neutral |
| Apr-03-19 | Downgrade | Canaccord Genuity | Hold → Sell |
| Jan-26-18 | Reiterated | Canaccord Genuity | Hold |
| Mar-28-17 | Initiated | CL King | Neutral |
| Mar-28-16 | Reiterated | Canaccord Genuity | Hold |
| Sep-10-15 | Reiterated | Canaccord Genuity | Hold |
| Jul-27-15 | Reiterated | Canaccord Genuity | Hold |
| May-04-15 | Reiterated | Canaccord Genuity | Hold |
| Nov-06-14 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jul-27-12 | Downgrade | Canaccord Genuity | Buy → Hold |
| Apr-25-11 | Upgrade | Wedbush | Underperform → Neutral |
| Mar-24-11 | Upgrade | Canaccord Genuity | Hold → Buy |
| Nov-16-10 | Initiated | Canaccord Genuity | Hold |
| Apr-07-10 | Initiated | Wedbush | Underperform |
| Nov-13-09 | Reiterated | Caris & Company | Average |
| Jul-07-09 | Initiated | Caris & Company | Average |
| Mar-06-09 | Initiated | William Blair | Mkt Perform |
View All
Meridian Bioscience Inc. Stock (VIVO) Latest News
ICE Mark Awarded to Meridian Bioscience for Alethia Molecular Assay Portfolio - Medical Product Outsourcing
Meridian Bioscience Achieves IVDR Certification for Alethia® Molecular Assay Portfolio - Bluefield Daily Telegraph
EU’s stricter test rules: Meridian Alethia assays clear IVDR hurdle - Stock Titan
Meridian Life Science Expands Ambient-Stable NGS Portfolio with the Launch of a Lyophilized Enzymatic DNA Fragmentation Kit - The Joplin Globe
IVD Contract Manufacturing Market Size to Reach USD 43.79 - GlobeNewswire
Cleveland biotech firm adds veteran CEO to lead board during growth phase - Crain's Cleveland Business
Shigella Test Kit Market 2026 Is Booming Worldwide by 2033 - openPR.com
Isothermal Nucleic Acid Amplification Technology Market to Worth Over US$ 17.26 Billion by 2033 | Astute Analytica - GlobeNewswire
NeoGenomics Adds Diagnostics Executive Jack Kenny To Board - Pulse 2.0
NeoGenomics Appoints Diagnostics and Lab Services Industry Veteran John P. “Jack” Kenny to its Board of Directors - BioSpace
Abilene Topic MERIDIAN BIOSCIENCE, INC. | News, Weather, Sports, Breaking News - KTXS
Rapid Medical Diagnostics Market Analysis 2025: Outlook in GCC - openPR.com
Multiplex PCR Kit Market Size to Lead at 10.64% CAGR by 2034 - GlobeNewswire
Yeast Infection Diagnostics Market Share Analysis | CAGR of 6.3% - Market.us
Breath Analyzers Market Opportunities, Key Trends, - openPR.com
United States Malaria Diagnostics Market 2025: Industry - openPR.com
2nd Ex-Magellan Exec Avoids Jail Over Faulty Lead Tests - Law360
Ex-CEO of Magellan Diagnostics avoids prison over lead-test device defect - Reuters
Bioline Launches ISOLATE II, a Precious Find for DNA and RNA Isolation - AOL.com
Shigella Test Kit Market Is Booming Worldwide 2025-2032 | Thermo - openPR.com
Feds, Ex-Magellan CEO Still Split Over Sentencing Factors - Law360
Helicobacter Pylori Non-Invasive Testing Market Size | CAGR 7.2% - Market.us
Growing Greater Cincinnati diagnostics company Meridian Bioscience names new CEO - The Business Journals
Meridian Bioscience, Inc. Announces Chief Financial Officer Changes, Effective October 14, 2025 - MarketScreener
Meridian Bioscience, Inc. Announces Executive Changes - MarketScreener
Meridian Bioscience, Inc. Promotes Andy Kitzmiller to Chief Executive Officer, Effective October 14, 2025 - MarketScreener
Meridian Bioscience Appoints New CEO and Executive Team to Accelerate Global Growth - WV News
Biotech firm to build new manufacturing facility in suburban Cincinnati - WKRC
Meridian Bioscience to create new advanced manufacturing facility in Cincinnati suburb - The Business Journals
Meridian Bioscience Eliminates Cold Chain with the First Liquid Ambient Temperature Stable qPCR Master Mixes - Eastern Progress
Chronic Hepatitis B Virus Testing Market | Global Market Analysis Report2035 - Future Market Insights
Meridian BioscienceFinancial Details - Crunchbase
Revenue of Meridian Bioscience Inc from 2018 to 2022 - Statista
Judge Casts Doubt On Plea Deals In Blood Test Defect Case - Law360
Helicobacter Pylori Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2036 - globaldata.com
Rapid Tests Market to Hit USD 3.08 Billion by 2032, Driven by Rising Demand for Quick Diagnostics | SNS Insider - GlobeNewswire
Influenza Diagnostics Market Size to Hit USD 2.45 Billion - GlobeNewswire
Former Magellan Diagnostics CEO pleads guilty over lead-test device defect - Reuters
Influenza Diagnostics Market Revenue to Exceed $2.0 Bn by 2031 Amid Rising Cases and Demand for Rapid Testing – TMR Insights - PharmiWeb.com
Former Magellan exec to plead guilty to concealing lead testing device defect - Reuters
TMU to recognize outstanding honorees at 27th Bishop William A. Hughes Award Dinner April 2 - NKyTribune
Europe Hospital Acquired Infections Diagnostics Market, 2030 - Grand View Research
Chlamydia Market Report 2034: Epidemiology Data, Pipeline - openPR.com
Point of Care (POC) Diagnostics Market to Grow by USD 16.42 Billion (2024-2028) Geriatric Population Boosts Growth, Report on AI-Powered Market EvolutionTechnavio - PR Newswire
Hiv 1 Testing Market Overall Study Report 2024-2032 | BioRad Laboratories ,Meridian Bioscience, Inc. ,Grifols ,BD - openPR.com
Population dynamics of sympatric Phortica spp. and first record of stable presence of Phortica oldenbergi in a Thelazia callipaeda-endemic area of Italy - Parasites & Vectors
Lead testing device company Magellan sentenced for concealing defects - Reuters
In Vitro Diagnostics Contract Manufacturing Market Report, 2030 - Grand View Research
Biosensors Market Size to Exceed USD 58.44 Billion by 2033 - BioSpace
Korean firms acquire US-based Meridian Bioscience for $1.53bn - Private Equity Insights
Judge questions 'unusual' DOJ plan to pay lead-testing device victims - Reuters
Meridian Bioscience Inc. Stock (VIVO) Financials Data
There is no financial data for Meridian Bioscience Inc. (VIVO). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.38%
1.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):